Pharmacy Times

SEPTEMBER 16, 2024

Abstracts from the OrigAMI-1 and MARIPOSA-2 trials indicated the treatment benefits of amivantamab-vmjw and chemotherapy in multiple cancer indications.

Chemotherapy 50

Chemotherapy 50

Hospital Pharmacy Europe

JANUARY 24, 2024

The final draft guidance from NICE recommends talazoparib for the treatment of adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer after prior chemotherapy. Evidence from a clinical trial showed that talazoparib increases how long people live without their cancer getting worse compared with chemotherapy.

Chemotherapy 101

Chemotherapy Hospitals 101

European Pharmaceutical Review

JUNE 27, 2024

Immunotherapy in oncology “The addition of pembrolizumab to chemotherapy represents a new frontline therapeutic option for patients with primary advanced or recurrent endometrial carcinoma” Moreover, last week saw US regulatory approval of a combination treatment for endometrial cancer : KEYTRUDA (pembrolizumab) plus chemotherapy.

Chemotherapy 64

Chemotherapy FDA 64

The Guardian - Pharmaceutical Industry

NOVEMBER 5, 2023

Exclusive: Regulator extends part suspension of licence to July 2024 after IT blunder led to incorrect dosage of cancer treatment A private health company paid millions by the NHS has failed to fix safety defects that led to the death of a cancer patient, the Guardian can reveal.

Chemotherapy 94

Chemotherapy Dosage 94

Pharmaceutical Technology

DECEMBER 11, 2024

The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnsons (J&J) Darzalex in combination with chemotherapy.

Chemotherapy 59

Chemotherapy 59

Pharmacy Times

DECEMBER 14, 2024

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Chemotherapy 65

Chemotherapy 65

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. months for chemotherapy. The overall survival rate at one year with Tedopi was 44.4 percent versus 27.5

Vaccines 98

Vaccines Chemotherapy Immunization 98

European Pharmaceutical Review

SEPTEMBER 25, 2023

The humanised IgG4 anti-PD-1 antibody is indicated for unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. The FDA’s target action date is the second half of 2024. months for chemotherapy. months for TEVIMBRA versus 6.3

Chemotherapy 105

Chemotherapy FDA Immunization 105

pharmaphorum

SEPTEMBER 6, 2022

The company’s lead drug PTX-061 is intended to improve the effectiveness of chemotherapy in patients with AML , which at the moment is only effective in around 20% of patients. The company said it will develop the new drug very quickly, and is eyeing regulatory filings with the FDA and EMA “as early as 2024.”

Chemotherapy 103

Chemotherapy Immunization FDA 103

European Pharmaceutical Review

MAY 20, 2024

This includes antibody production, chemotherapy drug and linker synthesis, conjugating the drug-linker to the antibody, as well as filling of the completed ADC substance, AstraZeneca confirmed. The pharmaceutical firm stated that it is planning to begin the design and construction of the manufacturing facility by the end of 2024.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. This initial data on ZL-1310 was presented this week at the EORTC-NCI-AACR (ENA) Symposium 2024.

Chemotherapy 97

Chemotherapy Compounding Immunization 97

Pharmaceutical Technology

SEPTEMBER 6, 2022

Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin. By 2024, doxorubicin is anticipated to have a market size of $1.38bn and is extensively utilised as a part of the standard of care in various types of cancers. . It also boosts the drug’s safety, tolerability and efficacy.

FDA 98

FDA Chemotherapy 98

European Pharmaceutical Review

JUNE 5, 2024

The updated analysis for the biologic Jemperli were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract LBA3512). Hesham Abdullah , Senior Vice President, Global Head Oncology, R&D, GSK noted that the data showing “no evidence of disease in 42 patients is remarkable”.

Chemotherapy 98

Chemotherapy 98

STAT

APRIL 11, 2024

Medicare actuaries expect the drug, which is called Leqembi and sold by Eisai in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024. That is projected to increase to $3.5 billion in 2025 for the entire Medicare program, a spokesperson for the Centers for Medicare and Medicaid Services confirmed.

Chemotherapy 97

Chemotherapy Immunization 97

STAT

NOVEMBER 5, 2024

Beam said the patient succumbed to respiratory failure, deemed to be “likely caused” by a regimen of chemotherapy required to prepare the patient for BEAM-101, a treatment that uses the company’s new, more precise form of CRISPR gene editing called base editing. The

Chemotherapy 88

Chemotherapy 88

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunization Hospitals 116

European Pharmaceutical Review

FEBRUARY 21, 2024

TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial. Results from a Phase III trial in the neoadjuvant setting are expected later in 2024. According to AstraZeneca, the small molecule treatment TAGRISSO is also being investigated in two Phase III trials.

Chemotherapy 105

Chemotherapy 105

PharmExec

DECEMBER 5, 2023

The FDA assigned a PDUFA date of April 5, 2024 for Opdivo (nivolumab) plus cisplatin-based chemotherapy for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

FDA 52

FDA Chemotherapy 52

pharmaphorum

MARCH 25, 2022

facility at Kent Science Park (KSP) in Sittingbourne is due to open in 2024, and when fully operational will create more than 100 new highly skilled jobs. If trials are successful, nabiximols could become one of the first additions to treatment for glioblastoma patients since temozolomide chemotherapy in 2007. The 60,000 sq.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

SEPTEMBER 16, 2021

The US regulator has cleared the tyrosine kinase inhibitor (TKI) as a second-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.

FDA 105

FDA Chemotherapy Vaccines 105

European Pharmaceutical Review

JANUARY 10, 2024

Patients who have undergone surgery for pancreatic cancer are still at risk for relapse of the disease, even after they finish chemotherapy. A Phase II trial will commence later in 2024, utilising a new formulation of the ELI-002 cancer vaccine, targeting additional KRAS mutations. This is compared to 4.01

Vaccines 98

Vaccines Chemotherapy 98

pharmaphorum

OCTOBER 4, 2020

However it requires high-dose chemotherapy to destroy the bone marrow, and that poses significant risks to patients in its own right, and can also lead to graft-versus-host disease, a potentially life-threatening complication in which the bone marrow donor’s immune cells attack the recipient’s cells and tissues.

Immunization 98

Immunization Chemotherapy FDA 98

PQA

NOVEMBER 1, 2024

We are excited to host members next week at the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease at the Renaissance Arlington Capital View Hotel in Arlington, Va. Thank you to our 2024 PQA Leadership Summit sponsors! There is still time for members to join us at both events!

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

Hospital Pharmacy Europe

MARCH 14, 2024

The monoclonal antibody dostarlimab (brand name Jemperli) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in combination with platinum-based chemotherapy for eligible patients with endometrial cancer. Publication of the final guidance is expected on 3 April 2024.

Chemotherapy 52

Chemotherapy Hospitals 52

pharmaphorum

JANUARY 23, 2023

The drug achieved an impressive 84% overall survival rate over 18 months in patients with advanced GEA who received it as a first-line therapy in combination with chemotherapy, according to data from the open-label study. GEA is the fifth most common cancer worldwide, and around one in five patients have tumours that are HER2-positive.

Chemotherapy 52

Chemotherapy Labelling 52

pharmaphorum

SEPTEMBER 2, 2021

The PANTHER trial looked at the combination of pevonedistat in combination with azacitidine chemotherapy as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and low-blast acute myeloid leukaemia (AML).

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

AUGUST 12, 2024

The deal is anticipated to be finalised in Q3 of 2024. It is the first anti-PD-1 therapy approved for use together chemotherapy in adults who have primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status.

Research Laboratories 59

Research Laboratories Chemotherapy FDA 59

Pharmaceutical Technology

MAY 2, 2023

Part of the proceeds will be used to fund our wholly owned pamrevlumab programme as we anticipate five Phase III readouts to occur before mid-2024.” FibroGen CEO Enrique Conterno stated: “With the current momentum across our development programmes, this financing strengthens our balance sheet.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

JUNE 15, 2023

PEMRYDI RTU is indicated as an initial treatment, along with pembrolizumab and platinum chemotherapy, for metastatic non-squamous non-small cell lung cancer patients with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberration.

FDA 52

FDA Chemotherapy 52

Hospital Pharmacy Europe

OCTOBER 14, 2024

On 31 May 2024, Dr Kunene led a team to administer the very first personalised vaccine against colorectal cancer in England as part of the pioneering NHS Cancer Vaccine Launch Pad (CVLP) initiative. Another treatment combination is chemotherapy with zolbetuximab – an antibody directed against claudin 18.6.

Vaccines 52

Vaccines Chemotherapy Hospitals Immunization 52

European Pharmaceutical Review

JUNE 27, 2023

difficile infection by the end of 2024 and will be announcing first patient dosed in the Phase II clinical trial of VE202 for ulcerative colitis (UC) shortly too. How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

European Pharmaceutical Review

DECEMBER 28, 2023

As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. We have now already treated the first patients and are expecting the first results from this study in the first half of 2024. 

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

PharmaShots

JUNE 19, 2023

This test can help veterinary professionals to detect kidney injury before it affects kidney function & may result in better patient outcomes The test will be conducted at IDEXX Reference Laboratories in the US & Canada with plans to roll out in the EU in 2024. IDEXX’s suite of kidney health diagnostics incl.

Chemotherapy 40

Chemotherapy 40

European Pharmaceutical Review

APRIL 10, 2024

4 Notably, microbiome therapies have strong potential in onco-haematology, where antibiotic and chemotherapy-derived loss of gut diversity is predictive of mortality in patients who have undergone an allogeneic haematopoietic stem cell transplant, as well as GvHD occurrence and infection. cited 2024Feb]. cited 2024Feb]. eClinicalMedicine.

Immunization 95

Immunization Chemotherapy FDA Pharmaceutical Companies 95

pharmaphorum

MARCH 8, 2022

In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy.

Chemotherapy 52

Chemotherapy Documentation Labelling 52

Hospital Pharmacy Europe

NOVEMBER 4, 2024

Durvalumab is ‘promising step forward’ The latest approval from the MHRA is based on positive data from the AEGEAN Phase III trial in rNSCLC , which showed that durvalumab-based treatment before and after surgery reduced the risk of recurrence, progression events or death by 32% versus neoadjuvant chemotherapy alone.

Chemotherapy 52

Chemotherapy Patient Care Clinic Management Hospitals 52

European Pharmaceutical Review

JULY 18, 2024

1,2 This is especially important in forms of cancer where chemotherapy remains the main treatment option. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy. Rise of Antibody-Drug Conjugates: The Present and Future.

Chemotherapy 59

Chemotherapy FDA 59